LENZ Therapeutics (LENZ) Gains from Investment Securities (2022 - 2025)

LENZ Therapeutics (LENZ) has disclosed Gains from Investment Securities for 4 consecutive years, with -$204000.0 as the latest value for Q3 2025.

  • Quarterly Gains from Investment Securities changed N/A to -$204000.0 in Q3 2025 from the year-ago period, while the trailing twelve-month figure was -$1.2 million through Sep 2025, changed N/A year-over-year, with the annual reading at $41000.0 for FY2024, 133.33% up from the prior year.
  • Gains from Investment Securities for Q3 2025 was -$204000.0 at LENZ Therapeutics, down from $204000.0 in the prior quarter.
  • The five-year high for Gains from Investment Securities was $1.0 million in Q1 2024, with the low at -$1.2 million in Q4 2024.
  • Average Gains from Investment Securities over 4 years is $115574.1, with a median of $91500.0 recorded in 2022.
  • Peak annual rise in Gains from Investment Securities hit 23.43% in 2024, while the deepest fall reached 23.43% in 2024.
  • Over 4 years, Gains from Investment Securities stood at $139055.0 in 2022, then tumbled by 92.54% to $10367.0 in 2023, then tumbled by 11327.93% to -$1.2 million in 2024, then skyrocketed by 82.47% to -$204000.0 in 2025.
  • According to Business Quant data, Gains from Investment Securities over the past three periods came in at -$204000.0, $204000.0, and -$1.2 million for Q3 2025, Q2 2025, and Q4 2024 respectively.